MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1

Li, Yaming; Liang, Yiran; Sang, Yuting; Song, Xinwei; Zhang, Hanwen; Liu, Ying; Jiang, Liyu; Yang, Qifeng

doi:10.1038/s41419-017-0030-7

Cited by 124 publications

(70 citation statements)

References 53 publications

(48 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Changes in the activity of sialic acid regulatory enzymes such as sialyltransferases and sialidase have been associated with diseased states in pregnancy such as gestational diabetes [41]. High expression of sialyltransferase have been reported in different cancers and shown to correlate with increase motility, invasion, and metastatic potential of tumour cells [59]. It is therefore interesting to observe the change in sialylation in our GTD samples and further question the significance of sialylation in hCG.…”

Section: Discussionmentioning

confidence: 83%

Insights into the hyperglycosylation of human chorionic gonadotropin revealed by glycomics analysis

et al. 2020

View full text Add to dashboard Cite

Human chorionic gonadotropin (hCG) is a glycoprotein hormone that is essential for the maintenance of pregnancy. Glycosylation of hCG is known to be essential for its biological activity. "Hyperglycosylated" variants secreted during early pregnancy have been proposed to be involved in initial implantation of the embryo and as a potential diagnostic marker for gestational diseases. However, what constitutes "hyperglycosylation" is not yet fully understood. In this study, we perform comparative N-glycomic analysis of hCG expressed in the same individuals during early and late pregnancy to help provide new insights into hCG function, reveal new targets for diagnostics and clarify the identity of hyperglycosylated hCG. hCG was isolated in urine collected from women at 7 weeks and 20 weeks' gestation. hCG was also isolated in urine from women diagnosed with gestational trophoblastic disease (GTD). We used glycomics methodologies including matrix assisted laser desorption/ ionisation-time of flight (MALDI-TOF) mass spectrometry (MS) and MS/MS methods to characterise the N-glycans associated with hCG purified from the individual samples. The structures identified on the early pregnancy (EP-hCG) and late pregnancy (LP-hCG) samples corresponded to mono-, bi-, tri-, and tetra-antennary N-glycans. A novel finding was the presence of substantial amounts of bisected type N-glycans in pregnancy hCG samples, which were present at much lower levels in GTD samples. A second novel observation was the presence of abundant Lewis X antigens on the bisected N-glycans. GTD-hCG had fewer glycoforms which constituted a subset of those found in normal pregnancy. When compared to EP-hCG, GTD-hCG samples had decreased signals for tri-and tetra-antennary N-glycans. In terms of terminal epitopes, GTD-hCG had increased signals for sialylated structures, while Lewis X antigens were of very minor abundance. hCG carries the same Nglycans throughout pregnancy but in different proportions. The N-glycan repertoire is more PLOS ONE | https://doi.

show abstract

Section: Discussionmentioning

confidence: 83%

Insights into the hyperglycosylation of human chorionic gonadotropin revealed by glycomics analysis

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Roscigno et al indicated that miRNA‐24 increases chemotherapy resistance of BC by hampering the chemotherapy‐induced apoptosis and also induces BC cell resistance to hypoxic conditions by affecting FIH1 − HIFα signaling pathway . Another example is the important role of exosomal miRNA‐770 in the reversion of doxorubicin‐resistance of TNBC cells by directly targeting the Stathmin 1 (STMN1) gene . miRNA‐105/93‐3p was also shown to induce chemoresistance, metastasis, and stemness in TNBC cells by activating Wnt/β‐catenin signaling pathway through downregulation of secreted frizzled related protein 1 (SFRP1) .…”

Section: Exosomal Mirnas In Bc Drug Resistancementioning

confidence: 95%

Emerging roles of exosomal miRNAs in breast cancer drug resistance

Najminejad

Kalantar

Abdollahpour‐Alitappeh³

et al. 2019

IUBMB Life

View full text Add to dashboard Cite

Breast cancer (BC), as a heterogeneous disease, is considered as one of the most common malignancies in women worldwide. The resistance of BC cells to therapeutic agents has remained a big challenge in the treatment of BC patients. Some factors such as cytokines, exosomes, and soluble receptors were recognized as crucial agents involved in the development of drug resistance. However, the exact mechanisms underlying the drug resistance is still unknown. There is growing evidence to support the emerging roles of exosomes, especially exosomal miRNAs, in tumor initiation, angiogenesis, proliferation, migration, invasion, metastasis, and drug resistance. Therefore, identification of BC-specific exosomal miRNAs and their underlying mechanisms would be helpful to define sensitivity to therapeutic drugs and establish an appropriate therapeutic strategy. This review focuses mainly on the roles of exosomal miRNAs and their associated mechanisms in the resistance of BC cells to therapeutic agents, as well as critically examines the potential of these macromolecules as a treatment biomarker in BC patients. K E Y W O R D Sbreast cancer, exosomes, drug resistance, therapeutics, exosomal miRNA, microRNA 1 | INTRODUCTION Breast cancer (BC), after skin cancer, was reported to be the most common malignancy in women worldwide. 1 Conversely, BC was showed to have a low incidence rate in men, approximately 1%. BC does not kill in primary stage. It was shown that the 5-year survival rates are 99%, 84%, and 23% for women with localized BC, regional stage, and

show abstract

“…Mature miRNAs are single‐stranded RNA molecules of 20–23 nucleotide (nt) length that control gene expression in many cellular processes. These molecules typically reduce the translation and stability of messenger RNAs (mRNAs; Li et al, ). As one of the important cellular mechanisms that regulate gene expression, miRNAs bind to the partially complementary sequences at the 3′‐untranslated regions (3′‐UTR) of the mRNAs of target genes, resulting in the degradation and/or blocking of translation of the mRNAs (Quan et al, ).…”

Section: Introductionmentioning

confidence: 99%

LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215

Kong

Duan

Sang

et al. 2018

Journal Cellular Physiology

Self Cite

204

131

View full text Add to dashboard Cite

Rapid proliferation and metastasis of breast cancers resulted in poor prognosis in clinic. Recent studies have proved that long noncoding RNAs (lncRNAs) were involved in tumor progression. In this study, we aimed to determine the roles and mechanisms of lncRNA–cell division cycle 6 (CDC6) in regulating proliferation and metastasis of breast cancer. Clinically, lncRNA–CDC6 was highly expressed in tumor tissues and was positively correlated with clinical stages of breast cancers. Functionally, the ectopic expression of lncRNA–CDC6 promoted proliferation via regulation of G1 phase checkpoint, and further promoting the migration capability. Moreover, lncRNA–CDC6 could function as competitive endogenous RNA (ceRNA) via directly sponging of microRNA‐215 (miR‐215), which further regulating the expression of CDC6. Taken together, our results proved that lncRNA–CDC6 could function as ceRNA and promote the proliferation and metastasis of breast cancer cells, which provided a novel prognostic marker for breast cancers in clinic.

show abstract

MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1

Cited by 124 publications

References 53 publications

Insights into the hyperglycosylation of human chorionic gonadotropin revealed by glycomics analysis

Insights into the hyperglycosylation of human chorionic gonadotropin revealed by glycomics analysis

Emerging roles of exosomal miRNAs in breast cancer drug resistance

LncRNA–CDC6 promotes breast cancer progression and function as ceRNA to target CDC6 by sponging microRNA‐215

Contact Info

Product

Resources

About